NAD Augmentation in Diabetes Kidney Disease
Purpose
A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.
Conditions
- Type2diabetes
- Diabetic Kidney Disease
Eligibility
- Eligible Ages
- Over 60 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Has T2DM, as indicated by any of the following: 1. Self-report of diabetes plus the use of a prescribed diabetes medication. 2. ICD-10 code for diabetes plus current use of a diabetes medication in the electronic medical record. 3. HbA1c >6.4%; or 2 fasting glucose > 125 mg/dL 2. Fasting morning UACR between 100 and 2,000 mg/g creatinine on two separate days 3. If UACR is > 300 mg/g creatinine, must be currently using an ACE inhibitor or an ARB 4. eGFR > 30 mL/ min / 1.73 m2 5. Hemoglobin A1c <9% 6. Able to speak English or Spanish 7. Willing and able to provide written informed consent 8. In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months
Exclusion Criteria
- Fasting morning UACR > 2,000 mg/ g creatinine 2. Other laboratory abnormalities: 1. Has AST or ALT > 3 times the upper limit of normal 2. creatinine > 2.5 mg/dL 3. Hematocrit < 0.34 or 0.50 L/L 3. A major adverse cardiovascular event in preceding 3 months 4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter 5. Hypoglycemia unawareness or other medical conditions which could jeopardize participant's safety. 6. History of alcohol or substance use disorder or dependence (DSM 5 criteria) within the last 2 years. 7. Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures. 8. BMI > 42.5 kg/ m2
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- This will be two center, randomized, double-blind, placebo-controlled, parallel group trial to determine whether βNMN, after its daily oral administration, is associated with a greater reduction in the UACR compared to placebo.
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Masking Description
- The study is double-blind in that the study participants and the study staff involved in outcomes assessments will be unaware of the intervention assignment. The randomization schedule will be masked from all study personnel except those specifically designated below. 1. The unblinded study biostatistician 2. The staff of the Investigational Drug Pharmacy Services. 3. The DSMB, if requested
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Investigational Product - MIB 626 |
The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily. |
|
|
Placebo Comparator Placebo |
Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC. |
|
Recruiting Locations
Brigham and Women's Hospital
Boston, Massachusetts 02115
Boston, Massachusetts 02115
More Details
- Status
- Recruiting
- Sponsor
- Brigham and Women's Hospital
Detailed Description
This will be two centers, randomized, double-blind, placebo-controlled, parallel group trial to determine whether βNMN, after its daily oral administration, is associated with a greater reduction in the UACR compared to placebo. The trial will enroll community-dwelling older adults, 60 years or older, with type 2 diabetes mellitus (T2DM) and urine albumin to creatinine excretion ratio > 100 mg/ g creatinine.